CSBio CSBio

X
[{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$417.0 million","upfrontCash":"$45.0 million","newsHeadline":"Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"AC Immune","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$105.1 million ","upfrontCash":"Undisclosed","newsHeadline":"AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer\u2122 Tau Partnership","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"AC Immune"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","amount":"$410.0 million","upfrontCash":"$45.0 million","newsHeadline":"Neurocrine Biosciences exercises option to license Idorsia's novel treatment for rare pediatric epilepsy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Anokion SA","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Anokion Initiates Patient Dosing in Phase 1 Trial of ANK-700 for the Treatment of Multiple Sclerosis","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Anokion SA"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asceneuron to Provide Update on O-GlcNAcase Pipeline at Upcoming Conferences","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Asceneuron"},{"orgOrder":0,"company":"Asceneuron","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ferrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Progressive Supranuclear Palsy (PSP)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Asceneuron"},{"orgOrder":0,"company":"Stalicla","sponsor":"Firefly Neuroscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"STALICLA and Firefly Neuroscience Enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Stalicla"},{"orgOrder":0,"company":"Stalicla","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","amount":"$17.4 million","upfrontCash":"Undisclosed","newsHeadline":"Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Stalicla"}]

Find Neurology Drugs in Phase I Clinical Development in SWITZERLAND

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            The proceeds will be utilized for the preparation of Stalicla’s pioneering precision Autism Spectrum Disorder (ASD) Phase 2 trial evaluating STP1, a fixed dose combination of PDE4/3 inhibitor (ibudilast) and NKCC1 antagonist (bumetanide).

            Lead Product(s): Ibudilast,Bumetanide

            Therapeutic Area: Neurology Product Name: STP1

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: SPRIM Global Investments

            Deal Size: $17.4 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing January 16, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            STALICLA and Firefly will leverage their technological platforms including the DEPI and BNA platform respectively to further advance EEG validation in two upcoming Phase 2 clinical trials including STALICLA’s lead asset STP1, a tailored treatment candidate for ASD-Phenotype 1.

            Lead Product(s): Ibudilast,Bumetanide

            Therapeutic Area: Neurology Product Name: STP1

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Firefly Neuroscience

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership March 27, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the licensing agreement, Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90, an O-GlcNAcase inhibitor, in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.

            Lead Product(s): ASN90

            Therapeutic Area: Neurology Product Name: ASN90

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ferrer Internacional

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement February 22, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ASN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathic disease, progressive supranuclear palsy (PSP), and was granted Orphan Drug Designation by the US FDA for the treatment of Progressive Supranuclear Palsy (PSP).

            Lead Product(s): ASN120290

            Therapeutic Area: Neurology Product Name: ASN120290

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 30, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The MoveS-it Study (Multiple Sclerosis Study of ANK-700 to Assess Safety and Immune Tolerance) is a randomized, double-blind, placebo-controlled, first-in-human study designed to evaluate the safety and tolerability of single and multiple ascending doses of ANK-700.

            Lead Product(s): ANK-700

            Therapeutic Area: Neurology Product Name: ANK-700

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 23, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (IT) formulation in older patients with SMA to further support registration.

            Lead Product(s): Onasemnogene abeparvovec

            Therapeutic Area: Neurology Product Name: AVXS-101

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 23, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Neurocrine Biosciences to develop and commercialize ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of a rare pediatric epilepsy.

            Lead Product(s): ACT-709478

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Neurocrine Biosciences

            Deal Size: $410.0 million Upfront Cash: $45.0 million

            Deal Type: Licensing Agreement May 11, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration combines AC Immune’s proprietary Morphomer discovery platform technology and early development experience with Lilly’s clinical development expertise and commercial capabilities.

            Lead Product(s): ACI3024

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: $105.1 million Upfront Cash: Undisclosed

            Deal Type: Collaboration March 23, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under this agreement, Neurocrine Biosciences owns option to exclusively license ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of epilepsy.

            Lead Product(s): ACT-709478

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Neurocrine Biosciences

            Deal Size: $417.0 million Upfront Cash: $45.0 million

            Deal Type: Licensing Agreement January 10, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY